233
Views
7
CrossRef citations to date
0
Altmetric
Articles

Onopordum illyricum L., a Mediterranean plant, as a source of anti HIV-1 compounds

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, , , , , , , ORCID Icon & ORCID Icon show all
Pages 1274-1281 | Received 24 Nov 2017, Accepted 07 Feb 2018, Published online: 18 Feb 2018
 

Abstract

Currently, many attempts have been made worldwide to isolate compounds from plants that could prevent transmission of HIV and offer new treatments. In this study, the methanolic extract of Onopordum illyricum aerial parts was evaluated for the inhibition of the HIV-1 reverse transcriptase (RT) ribonuclease H (RNase H), an attractive target for the identification of new antiretroviral inhibitors. Using an HIV-1 reverse transcriptase (RT)-associated RNase H inhibition assay, the bio-guided fractionation of the extract led to the isolation of seven compounds (luteolin, apigenin, hispidulin, arctiin, 1,5-dicaffeoylquinic acid, and two germacranes, 8α-(5-hydroxy)-angeloylsalonitenolide and onopordopicrin). Among them, luteolin was the most effective on RNase H RT-associated function (IC50 of 12.8 μM), followed by 1,5-dicaffeoylquinic acid and apigenin with IC50 values of 16.9 and 59.6 μM, respectively. Pure compounds were then assayed for their effects also on HIV-1 integrase (IN). 1,5-Dicaffeoylquinic acid, arctiin, onopordopicrin, and luteolin exhibited the most potent inhibition with IC50 values ranging from 0.50 to 22.5 μM. 1,5-Dicaffeoylquinic acid was also able to inhibit the early stages of HIV-1 replication in cell-based assays.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.